Olmesartan Medoxomil/Amlodipine Accord Healthcare (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil/Amlodipine is indicated for hypertension, a condition characterized by elevated arterial pressure.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with concomitant edema: provides vasodilation while counteracting calcium‑channel blocker‑induced fluid retention.
• Hypertension in patients requiring dual‑action therapy: combines renin‑angiotensin blockade with calcium‑channel blockade for enhanced blood‑pressure control.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing dose‑dependent arterial dilation. Together, the combination reduces peripheral resistance and lowers blood pressure through complementary mechanisms acting on the renin‑angiotensin system and calcium‑channel pathways.

Side effects reported with the fixed‑dose combination are generally consistent with the individual components.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after the first dose.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Nasal congestion: mild nasal stuffiness.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of lips, tongue or airway.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: elevated liver enzymes.
• Hyperkalemia: increased serum potassium levels.
• Acute kidney injury: sudden decline in renal function.
• Myocardial infarction: rare but reported cardiac events.

When prescribing Olmesartan Medoxil/Amlodipine, clinicians should consider patient‑specific factors and monitor for adverse reactions.

• Renal impairment: assess kidney function before initiation and periodically thereafter.
• Hepatic disease: use with caution in patients with liver dysfunction.
• Electrolyte imbalance: monitor serum potassium, especially if combined with potassium‑sparing diuretics.
• Pregnancy: contraindicated; drug may cause fetal toxicity.
• Elderly patients: start at lower dose and titrate slowly.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren: concurrent use in diabetic patients increases risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: may increase lithium levels, risking toxicity.
• Dual renin‑angiotensin system blockade (ACE inhibitors, ARBs): heightens risk of hypotension, renal dysfunction, and hyper‑kalaemia.